Letters Human papillomavirus vaccination

Glimpse into the black box of human papillomavirus vaccination

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a1046 (Published 28 July 2008) Cite this as: BMJ 2008;337:a1046
  1. Peter M English, consultant in public health medicine1,
  2. Keith Neal, professor, epidemiology of infectious diseases, epidemiology and public health 2
  1. 1Surrey KT19 9XF
  2. 2University of Nottingham, NG7 2RH
  1. petermbenglish{at}gmail.com

    We welcome an opportunity to get a glimpse into the black box underlying the recent decisions about human papillomavirus (HPV) vaccination.1 We would like to reflect on the assumptions made. GlaxoSmithKline claims that Cervarix will provide protection longer, which would favour Cervarix. The paper by Jit et al does not reflect this (which is probably appropriate, since these claims are disputed).

    The paper’s assumption that those …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial